Great outcome. The fact that this work has been trialed in the US, the global COVID hotspot, and very far from over, is really going to put MSB on the US investor's radar.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-51
-
- There are more pages in this discussion • 797 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $3.105M | 2.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 80347 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 53287 | 22 |
View Market Depth
| Last trade - 13.48pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |